Table 1.
Characteristics of metastatic NSCLC patients
| N | (%) | |
|---|---|---|
| Age (yrs) | 58 years (range 29-76) | 100 |
| Gender | ||
| Male | 36 | 60 |
| Female | 24 | 40 |
| Performance status | ||
| 0 | 14 | 23.3 |
| 1 | 41 | 68.3 |
| 2 | 5 | 8.3 |
| Histology | ||
| Large-cell carcinoma | 8 | 13.3 |
| Adenocarcinoma | 39 | 65 |
| Squamous cell carcinoma | 13 | 21.7 |
| Smoking history | ||
| Current smoker | 22 | 36.7 |
| Never smoked | 7 | 11.7 |
| Former smoker | 20 | 33.3 |
| Unknown | 11 | 18.3 |
| Number of chemotherapy lines | ||
| 1 | 18 | 30 |
| ≥2 | 42 | 70 |
| Metastatic site | ||
| Lung | 25 | 41.7 |
| Bone | 23 | 38.3 |
| Brain | 10 | 10 |
| Liver | 4 | 6.7 |
| Pleura | 8 | 13.3 |
| Adrenal | 8 | 13.3 |
| Skin | 1 | 1,7 |
| Others | 4 | 6.7 |
| EGFR mutations (51 patients screened) | ||
| del 19 | 7 | 13.7 |
| L858R | 2 | 3.9 |
| Total | 9 | 17.6 |
| K-ras mutations (56 patients screened) | 10 | 17.8 |
| First-line therapy | ||
| Chemotherapy | 52 | |
| Erlotinib | 7 | |
| Chemotherapy + erlotinib | 1 | |
| Response | ||
| Complete response | 5 | 8.9 |
| Partial response | 28 | 50 |
| Stable disease | 5 | 8.9 |
| Progressive disease | 13 | 23.2 |
| Not measurable | 9 | 8.9 |